What further tests are needed for a biopsy-confirmed squamous cell carcinoma (SCC) of the lower extremities?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

For a biopsy-confirmed squamous cell carcinoma (SCC) of the leg, further testing should include an ultrasound-guided FNA or surgical biopsy of regional lymph nodes if they are clinically palpable, as recommended by the British Journal of Dermatology study 1. When evaluating regional lymph nodes, it is essential to consider the potential for metastatic SCC. According to the study 1, if regional lymph nodes are clinically palpable, an ultrasound-guided FNA (or surgical biopsy if FNA results are inconclusive) should be performed to assess for the presence of SCC.

  • If the lymph node biopsy is positive for metastatic SCC, regional lymph node dissection should be considered, which can usually be carried out at the time of surgical excision of the primary SCC, as suggested by the study 1.
  • Sentinel lymph node biopsy (SLNB) may be undertaken, but its effectiveness in informing prognosis or influencing clinical outcome in patients with SCC is still unclear, as noted in the study 1.
  • Regional lymph node clearance should be considered if there is evidence of nodal disease on FNA or biopsy, as it may reduce subsequent problems from ulceration and local complications of secondary tumor deposits, as recommended by the study 1. It is crucial to carefully evaluate and manage SCC of the leg, as it can be invasive and potentially metastasize if not properly managed, highlighting the importance of thorough testing and staging.

From the Research

Further Tests for Biopsy-Confirmed Squamous Cell Carcinoma of the Legs

  • For patients with high-risk cutaneous squamous cell carcinoma (SCC), further tests such as sentinel lymph node biopsy (SLNB) may be necessary to determine the presence of subclinical lymph node metastasis 2, 3.
  • SLNB has been shown to accurately diagnose subclinical lymph node metastasis with few false-negative results and low morbidity 2.
  • The decision to perform SLNB should be based on the individual patient's risk factors and clinical context, as the utility of SLNB in SCC is still being investigated 2, 3.
  • Other diagnostic imaging techniques such as dermoscopy and reflectance confocal microscopy may also be useful in the diagnosis and monitoring of SCC 4.
  • For patients with SCC in situ of the lower extremity, treatment options such as local destruction, excision, or topical therapy may be effective, and patient-reported outcomes can be used to evaluate the success of these treatments 5.

Considerations for Sentinel Lymph Node Biopsy

  • The false-negative rate and negative predictive value of SLNB may vary depending on the location of the tumor, with higher rates reported for tumors of the trunk and extremities compared to the head and neck 3.
  • The use of SLNB in oral squamous cell carcinoma is also being investigated, with recent studies demonstrating its potential clinical utility 6.
  • Factors such as depth of invasion, nodal mapping, histopathology methods, operator variability, and postoperative complications should be considered when deciding whether to perform SLNB 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Sentinel lymph node biopsy in cutaneous squamous cell carcinoma: a systematic review of the English literature.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2006

Research

Squamous Cell Carcinoma: An Update on Diagnosis and Treatment.

Dermatology practical & conceptual, 2020

Research

Treatment of squamous cell carcinoma in situ of the lower extremity: a study of patient-reported outcomes.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2019

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.